| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 INSERM U271, 151 cours A. Thomas, 69003 Lyon, France
2 Department of Pediatrics, Hôpital Edouard Herriot, Lyon, France
Correspondence
Alan Kay
kay{at}lyon.inserm.fr
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
The GenBank/EMBL/DDBJ accession number for the sequence determined in this work is AJ748098.
|
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
), although other models exist (Chen et al., 1996)], which is exposed on the surface of viral particles. The major antigenic determinant in this region is the a determinant (residues 124–147), but other important determinants exist, such as the d/y determinants, which are defined by the nature of the residue at position 122 of HBsAg (Arg or Lys, respectively) and the r/w determinants at position 160 (again Arg or Lys) (Kidd-Ljunggren et al., 2002; Norder et al., 1992, 2004). In adults with acute HBV infection, over 90 % develop anti-HBs antibodies and clear the virus permanently (Robinson, 1999). HBsAg is also the major component of HBV vaccines, sometimes in association with a minor envelope protein, the middle surface antigen (preS2 protein). Anti-HBs titres of >10 IU l–1 are generally considered to be protective (Jack et al., 1999). Neonatal vaccination in areas highly endemic for HBV infection has proved to be highly effective (Hino et al., 2001; Kao & Chen, 2002; Poovorawan et al., 2000; Viviani et al., 1999), but breakthrough infections can occur, in most cases presumably due to non-response or poor response to vaccination. The effectiveness of the anti-HBs response is due, at least in part, to the limited variability of HBsAg that the virus can tolerate (Mizokami et al., 1997; Ogura et al., 1999; Torresi, 2002; Zollner et al., 2001), the reading frame for HBsAg being overlapped completely by a region of the P gene that encodes vital functional domains of the viral polymerase. However, with the advent of mass vaccination, so-called vaccine-escape mutants have emerged (Basuni & Carman, 2004; Chen & Oon, 1999; Zuckerman & Zuckerman, 1999, 2003). These mutants can in fact be detected, albeit very infrequently, in the non-vaccinated population (Oon & Chen, 1998). Most of the escape mutants described so far contain substitutions within or in proximity to the a determinant (Oon et al., 1999). It is thought that these substitutions alter the structure of the a determinant in such a way that the virus remains viable, but is able to avoid surveillance by anti-HBs antibodies. The corollary is that, at least initially, these mutant antigens are recognized poorly or not at all by the commercial HBsAg detection assays (Coleman et al., 1999; Ireland et al., 2000). The fact that these mutations have not become fixed in the general HBV population during the course of evolution indicates that the mutants are less fit than the ‘wild-type’ viruses, as a result of either the mutations also affecting the overlapping P gene or the altered structure of HBsAg reducing infectivity. However, the existence of these mutants creates a situation in which there is circulating HBV, despite the presence of significant levels of anti-HBs. We describe here a similar situation, but one in which the circulating virus is apparently ‘wild-type’, and put forward a mechanism of immune escape that appears to be the most probable reason for the existence of this situation. |
METHODS |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
. All sera used in this study were obtained during regular consultations. The foster-parents had signed an informed-consent letter.
|
) and Platinum Taq High Fidelity DNA polymerase (Invitrogen). After purification with Wizard PCR Preps (Promega), the PCR fragment was sequenced directly by using HBV-specific primers and a BigDye terminator Ready Reaction kit (Applied Biosystems). Sequencing reactions were analysed on an Applied Biosystems Prism 377 automated-sequencing machine. For the August 2002 sample, each nucleotide was checked at least twice and, except for the two extremities, which could be sequenced in only one direction by direct sequencing, the genome was sequenced fully on both strands. The genomic sequence has been deposited in GenBank under accession no. AJ748098. For cloning, the PCR fragment was digested with restriction enzymes HindIII and SacI, whose restriction sites were contained within the two primers used for PCR amplification. The genome was then ligated into pGEM-3Zf(+) (Promega), which had been digested with the same enzymes. The region encoding HBsAg was amplified from the June 2003 sample by using the primers Pol1 (5'-CCTGCTGGTGGCTCCAGTTC-3', nt 56–75) and Por4 (5'-TACCCAAAGACAAAAGAAAATTGG-3', nt 826–803) and AmpliTaq DNA polymerase (Perkin Elmer). After purification, the PCR fragment was cloned directly into pGEM-T (Promega).
Cell transfection and measurement of HBV DNA, mRNA and HBsAg-expression levels.
HuH7 cells, a human hepatocyte cell line, were grown and transfected as described previously (Jeantet et al., 2002). Two HBV genomes were used: the cloned Z1 genome and a control ‘wild-type’ genome, 15803 (GenBank accession no. AJ344117), of genotype D isolated from a typical chronic HBV carrier and amplified by the same one-step PCR used for Z1. Five days after transfection, total extra- and intracellular nucleic acids were extracted and HBV DNA and RNA levels were measured by hybridization as described previously (Jeantet et al., 2002). Extra- and intracellular expression of HBsAg was measured by using the Monolisa AgHBs Plus Detection Assay (Bio-Rad).
35S-Labelling.
HuH7 cells were grown and transfected as described above except that the cells were grown in Dulbecco's modified Eagle's medium (DMEM). Three HBV genomes were transfected: Z1, which encoded an HBsAg of serotype adr; 15803, which encoded an HBsAg of serotype ayw; and CS, which also encoded an HBsAg of serotype adr, but which was isolated from a typical chronic HBV carrier. The plasmid containing the CS genome, which had also been amplified by the one-step PCR method, was a generous gift of Dr Camille Sureau, INSERM U76, INTS, Paris, France, who also supplied the unpublished sequence of the genome. Three days after transfection, the cells were starved for 2 h by using DMEM without L-cys and L-Met or 10 % dialysed fetal bovine serum. The medium was then removed and replaced with 1 ml per well of the same medium containing 200 µCi (7·4 MBq) [35S]L-cys and [35s]L-Met ml–1. The cells were labelled for 24 h and the medium was then collected and clarified by centrifugation at 800 g for 5 min.
Immunoprecipitation.
Clarified medium (300 µl) was diluted with an equal volume of 10 mM Tris/HCl (pH 7·4), 150 mM NaCl, 1 mM EDTA, 2 % BSA (TNE-BSA) and 5 µl antiserum was added. Three antisera were used: the August 2002 serum of Z1, an anti-HBs-positive serum (AK) and an anti-HBs-negative serum (AK-PI). Sera AK and AK-PI came from one of the authors, who had been initially vaccinated and boosted with Genhevac B, which contains an HBsAg of serotype ayw, and was reboosted 7 years later with Engerix B, which contains an HBsAg of serotype adw. The anti-HBs titre of serum AK was 1000 IU l–1. AK-PI was the pre-immune serum collected before the first HBV vaccination. The mixtures were incubated on a rotating wheel for 90 min at 4 °C. A 20 % (v/v) suspension of Protein A–Sepharose CL-4B (Amersham Biosciences) in TNE-BSA (100 µl) was then added to each tube and incubation was continued for a further 90 min. The tubes were centrifuged briefly, the supernatants were removed and the beads were washed four times with 1 ml TNE-BSA. In order to keep the viral particles in their native form, detergents were avoided. The beads were transferred to clean tubes by using water, centrifuged and, after removal of the supernatants, the beads were dried under vacuum and resuspended in 30 µl sample loading buffer [Tris/HCl (pH 6·8), 2 % SDS, 5 % 2-mercaptoethanol, 10 % glycerol, 0·001 % bromophenol blue]. After boiling for 5 min, 15 µl aliquots were analysed by SDS-PAGE (12 % gel; acrylamide : bis-acrylamide, 30 : 0·8). After electrophoresis, the gels were fixed, impregnated with En3Hance fluor (Perkin Elmer), dried and exposed to autoradiography film at –70 °C for 1–3 days. Films were scanned and the results were mounted in PowerPoint.
Mutagenesis.
The cloned Z1 genome was mutagenized by using a QuikChange Mutagenesis kit (Stratagene) and the oligonucleotide 5'-GGACCATGCARGACCTGCACGAYTCCTGCTCAA-3' (nt 509–541) and its complement. By using degenerate nucleotides, all three of the desired mutants (Z1-122R, Z1-126I and Z1-122R126I) could be obtained in one mutagenesis reaction. In addition, the nucleotide changes conformed to the sequence of the isolate with GenBank accession no. AF223955 and did not affect the overlapping polymerase gene. In addition, changing nt 519 from A to G introduced a new PpuMI restriction site and changing nt 531 from C to T introduced a new TfiI site. These were used for initial screening of the clones obtained after mutagenesis. One clone of each type was selected and the HBsAg-coding regions were sequenced to make sure that only the desired mutations had been introduced. The three constructions, along with the original Z1 genome, were transfected into HuH7 cells, which were then 35S-labelled. Viral particles were immunoprecipitated as described above.
|
RESULTS |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
). He was and has remained asymptomatic. During a routine check-up in April 2002, he was found to have not only a moderately high level of viraemia (>5x107 copies ml–1), but also a high titre of anti-HBs antibodies (>600 IU l–1). By August 2002, the viraemia had increased tenfold and has remained high since then, as have his anti-HBs titres, although these have decreased slowly over time (Table 1). Suspecting the presence of an immune-escape mutant, full-length HBV genomes from Z1 were amplified and sequenced. The genome was found to be genotype C (Fig. 1) and, more particularly, a C-1858 variant that is found in South-East Asia, including Vietnam (Alestig et al., 2001). To our surprise, the sequence was apparently ‘wild-type’, with the notable exception of an 18 nt deletion involving the ATG codon normally used for initiation of the preS1 protein. However, many HBV genomes have deletions in this region and several have a deletion identical to that of the Z1 genome, including two C-1858 variants (Fig. 1). A viable preS1 protein can be initiated at an in-phase ATG codon 13 codons downstream from the normal initiation codon, and HBV genotype D naturally has such a truncated preS1 protein. The genome of Z1 encoded an HBsAg of serotype adr, with residues 122 and 160 being Lys and Arg, respectively (Table 2; Fig. 2). When compared with the consensus HBsAg sequence of C-1858 variants, the HBsAg of Z1 differed at only two positions, residues 5 and 126. A Ser residue at position 5 is rare in human HBsAg, but has been found in strains from Vietnam (Hannoun et al., 2000). A Thr at position 126 is very common in HBV isolates, including those of genotype C.
|
|
|
The first hypothesis to explain the paradox between circulating ‘wild-type’ HBV and high levels of anti-HBs is that the Z1 genome overexpresses HBsAg, thereby swamping the anti-HBs humoral immune response. However, when the Z1 genome and a control ‘wild-type’ genome (15803) isolated from a typical chronic HBV carrier were transfected into HuH7 cells, there were no significant differences in the levels of HBV DNA or RNA synthesized, including HBsAg mRNA, or in HBsAg expression and secretion (not shown).
To see what the serum of Z1 was capable of recognizing, viral particles were 35S-labelled after transfection of full-length genomes into HuH7 cells and immunoprecipitated. Three genomes were used: Z1, 15803 encoding HBsAg of serotype ayw, and CS, a ‘wild-type’ genome that, like Z1, encodes an HBsAg of serotype adr, but which was isolated from a typical chronic HBV carrier. Three sera were used: Z1 serum, an anti-HBs-positive serum (AK) and an anti-HBs-negative serum (AK-PI). Sera AK and Z1 recognized the serotype ayw HBsAg equally well (Fig. 3). Conversely, whilst serum AK efficiently recognized HBsAg expressed by genomes Z1 and CS, these antigens were recognized poorly by Z1 serum.
|
). Whilst most C-1858 variants code for HBsAg of serotype adr, one (GenBank accession no. AF223955) encodes an HBsAg of serotype ayr. The HBV genome of Z1 was therefore modified to convert residue 122 of HBsAg to Arg (Z1-122R, serotype ayr). As Z1 serum seemed to recognize HBsAg expressed by the CS genome somewhat better than that expressed by its own genome (Fig. 3), a Z1-126I construction was also made, as was a double mutant (Z1-122R126I). Conversion of residue 122 from Lys to Arg resulted in recognition of the modified HBsAg by Z1 serum as well as, if not better than, that of the control anti-HBs positive serum (Fig. 4). Changing residue 126 from Thr to Ile seemed to have little effect.
|
|
DISCUSSION |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
), the emergence of vaccine-escape mutants (Basuni & Carman, 2004), most of which involve single-base substitutions, and the fact that such mutations can be found in the non-vaccinated population (Oon & Chen, 1998). There is a precedent for point mutations changing subtype determinants (Okamoto et al., 1987); that study described patients expressing HBsAgs of either subtypes adr and ayr, or adr and adw. Two HBV genomes were found in each patient that differed in their S genes by only the point mutations that affect the subtype specificities and, in the complete genomes, there were, at most, ten differences between the two genomes. The authors concluded that point mutations within one original genome were responsible for the mixed HBsAg subtypes, which could co-exist as the patients, unlike Z1, had not mounted an anti-HBs response against one of the subtype epitopes. Incidentally, our study showed that an anti-HBs response directed against a subtype epitope can be neutralizing, as Z1 has successfully eliminated the viral population that originally expressed the y epitope.
How frequent are such cases? In the 1970s, there were several reports of co-existence of HBsAg and anti-HBs, with discrepancies between the serotype of circulating HBsAgs and the serotypes recognized by the sera (Koziol et al., 1976; Le Bouvier et al., 1976; Sasaki et al., 1976). In one study, out of 140 consecutive HBsAg-positive blood donors, three (2·1 %) also had heterotypic anti-HBs (Le Bouvier et al., 1976), a prevalence that is low, but not negligible. However, the limited analytical tools available at that time meant that the studies were descriptive, although the conclusions that were drawn were remarkably prescient. Here, we provide evidence for the molecular and immunological basis of the phenomenon. More recently, leaving aside immune-escape mutant cases, there have also been reports of co-existence of HBV and anti-HBs, but involving low levels of viraemia that can only be detected by PCR (Bahn et al., 1997) or borderline anti-HBs titres (Zaaijer et al., 2002). Only one reported case (Kohno et al., 1996) seems similar to that of Z1, the HBsAg also being ‘wild-type’ for serotype adr. In a haemagglutination test, the patient's serum did not recognize HBsAg of serotype adr, but did recognize HBsAg of serotype adw. This, therefore, seems to be a case of epitope switching, involving not the d/y determinant but the r/w determinant. Viraemia (107 copies ml–1) and anti-HBs titres (162 IU l–1) were both lower than in patient Z1, but the patient was older (23 years) and this may reflect virus–host adaptation.
What are the implications for HBV vaccination? This study illustrates the intricacies of the virus–host relationship. Z1 had mounted an anti-HBs response far stronger than that considered to be protective, but the humoral (and presumably also the T-cell) response was insufficiently broad. This left open a loophole that permitted a ‘wild-type’, and therefore fit, virus to replicate freely. If naturally infected individuals who are confronted with a full range of potential neutralization epitopes, not only on HBsAg but also on the minor envelope proteins, can sometimes mount a quasi-monoclonal response to one epitope, this may also be true for some vaccinated individuals. It is possible that some cases of vaccine escape, especially those involving mutations outside the a determinant, may be due to a humoral response that is limited in scope. Only close study of breakthrough patients in mass-vaccination programmes can answer this point. If this turns out to be a problem, then it may be necessary to increase the variety of the epitopes present in vaccines. This could involve using mixtures of HBsAgs, for example adw/ayr or adr/ayw, as well as the introduction of the minor envelope proteins.
|
ACKNOWLEDGEMENTS |
|---|
|
REFERENCES |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
Bahn, A., Gerner, P., Martiné, U., Bortolotti, F. & Wirth, S. (1997). Detection of different viral strains of hepatitis B virus in chronically infected children after seroconversion from HBsAg to anti-HBs indicating viral persistence. J Hepatol 27, 973–978.[CrossRef][Medline]
Basuni, A. A. & Carman, W. F. (2004). HBV vaccine-escape variants. Methods Mol Med 95, 115–124.[Medline]
Chen, W. N. & Oon, C. J. (1999). Human hepatitis B virus mutants: significance of molecular changes. FEBS Lett 453, 237–242.[CrossRef][Medline]
Chen, Y.-C. J., Delbrook, K., Dealwis, C., Mimms, L., Mushahwar, I. K. & Mandecki, W. (1996). Discontinuous epitopes of hepatitis B surface antigen derived from a filamentous phage peptide library. Proc Natl Acad Sci U S A 93, 1997–2001.
Coleman, P. F., Chen, Y.-C. J. & Mushahwar, I. K. (1999). Immunoassay detection of hepatitis B surface antigen mutants. J Med Virol 59, 19–24.[CrossRef][Medline]
Günther, S., Li, B.-C., Miska, S., Krüger, D. H., Meisel, H. & Will, H. (1995). A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J Virol 69, 5437–5444.[Abstract]
Hannoun, C., Horal, P. & Lindh, M. (2000). Long-term mutation rates in the hepatitis B virus genome. J Gen Virol 81, 75–83.
Hino, K., Katoh, Y., Vardas, E., Sim, J., Okita, K. & Carman, W. F. (2001). The effect of introduction of universal childhood hepatitis B immunization in South Africa on the prevalence of serologically negative hepatitis B virus infection and the selection of immune escape variants. Vaccine 19, 3912–3918.[CrossRef][Medline]
Ireland, J. H., O'Donnell, B., Basuni, A. A., Kean, J. D., Wallace, L. A., Lau, G. K. & Carman, W. F. (2000). Reactivity of 13 in vitro expressed hepatitis B surface antigen variants in 7 commercial diagnostic assays. Hepatology 31, 1176–1182.[CrossRef][Medline]
Jack, A. D., Hall, A. J., Maine, N., Mendy, M. & Whittle, H. C. (1999). What level of hepatitis B antibody is protective? J Infect Dis 179, 489–492.[CrossRef][Medline]
Jeantet, D., Chemin, I., Mandrand, B., Zoulim, F., Trepo, C. & Kay, A. (2002). Characterization of two hepatitis B virus populations isolated from a hepatitis B surface antigen-negative patient. Hepatology 35, 1215–1224.[CrossRef][Medline]
Kao, J.-H. & Chen, D.-S. (2002). Global control of hepatitis B virus infection. Lancet Infect Dis 2, 395–403.[CrossRef][Medline]
Kidd-Ljunggren, K., Miyakawa, Y. & Kidd, A. H. (2002). Genetic variability in hepatitis B viruses. J Gen Virol 83, 1267–1280.
Kohno, H., Inoue, T., Tsuda, F., Okamoto, H. & Akahane, Y. (1996). Mutations in the envelope gene of hepatitis B virus variants co-occurring with antibody to surface antigen in sera from patients with chronic hepatitis B. J Gen Virol 77, 1825–1831.
Koziol, D. E., Alter, H. J., Kirchner, J. P. & Holland, P. V. (1976). The development of HBsAg-positive hepatitis despite the previous existence of antibody to HBsAg. J Immunol 117, 2260–2262.
Le Bouvier, G. L., Capper, R. A., Williams, A. E., Pelletier, M. & Katz, A. J. (1976). Concurrently circulating hepatitis B surface antigen and heterotypic anti-HBs antibody. J Immunol 117, 2262–2264.
Mizokami, M., Orito, E., Ohba, K., Ikeo, K., Lau, J. Y. N. & Gojobori, T. (1997). Constrained evolution with respect to gene overlap of hepatitis B virus. J Mol Evol 44 (Suppl. 1), S83–S90.
Norder, H., Couroucé, A.-M. & Magnius, L. O. (1992). Molecular basis of hepatitis B virus serotype variations within the four major subtypes. J Gen Virol 73, 3141–3145.
Norder, H., Couroucé, A.-M., Coursaget, P., Echevarria, J. M., Lee, S.-D., Mushahwar, I. K., Robertson, B. H., Locarnini, S. & Magnius, L. O. (2004). Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology 47, 289–309.[CrossRef][Medline]
Ogura, Y., Kurosaki, M., Asahina, Y., Enomoto, N., Marumo, F. & Sato, C. (1999). Prevalence and significance of naturally occurring mutations in the surface and polymerase genes of hepatitis B virus. J Infect Dis 180, 1444–1451.[CrossRef][Medline]
Okamoto, H., Imai, M., Tsuda, F., Tanaka, T., Miyakawa, Y. & Mayumi, M. (1987). Point mutation in the S gene of hepatitis B virus for a d/y or w/r subtypic change in two blood donors carrying a surface antigen of compound subtype adyr or adwr. J Virol 61, 3030–3034.
Oon, C.-J. & Chen, W. N. (1998). Current aspects of hepatitis B surface antigen mutants in Singapore. J Viral Hepat 5 (Suppl. 2), 17–23.
Oon, C.-J., Chen, W. N., Koh, S. & Lim, G. K. (1999). Identification of hepatitis B surface antigen variants with alterations outside the "a" determinant in immunized Singapore infants. J Infect Dis 179, 259–263.[CrossRef][Medline]
Persson, B. & Argos, P. (1994). Prediction of transmembrane segments in proteins utilising multiple sequence alignments. J Mol Biol 237, 182–192.[CrossRef][Medline]
Poovorawan, Y., Theamboonlers, A., Vimolket, T. & 7 other authors (2000). Impact of hepatitis B immunisation as part of the EPI. Vaccine 19, 943–949.[Medline]
Robinson, W. S. (1999). Hepadnaviruses (Hepadnaviridae): hepatitis B virus: general features. In Encyclopedia of Virology, 2nd edn, pp. 640–645. Edited by A. Granoff & R. G. Webster. San Diego: Academic Press.
Sasaki, T., Ohkubo, Y., Yamashita, Y., Imai, M. & Miyakawa, Y. (1976). Co-occurrence of hepatitis B surface antigen of a particular subtype and antibody to a heterologous subtypic specificity in the same serum. J Immunol 117, 2258–2259.
Torresi, J. (2002). The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J Clin Virol 25, 97–106.[Medline]
Viviani, S., Jack, A., Hall, A. J., Maine, N., Mendy, M., Montesano, R. & Whittle, H. C. (1999). Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age. Vaccine 17, 2946–2950.[CrossRef][Medline]
Zaaijer, H. L., Lelie, P. N., Vandenbroucke-Grauls, C. M. J. E. & Koot, M. (2002). Concurrence of hepatitis B surface antibodies and surface antigen: implications for postvaccination control of health care workers. J Viral Hepat 9, 146–148.[Medline]
Zöllner, B., Petersen, J., Schröter, M., Laufs, R., Schoder, V. & Feucht, H.-H. (2001). 20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw. Lancet 357, 934–935.[CrossRef][Medline]
Zuckerman, A. J. & Zuckerman, J. N. (1999). Molecular epidemiology of hepatitis B virus mutants. J Med Virol 58, 193–195.[Medline]
Zuckerman, J. N. & Zuckerman, A. J. (2003). Mutations of the surface protein of hepatitis B virus. Antiviral Res 60, 75–78.[CrossRef][Medline]
Received 7 December 2004;
accepted 17 February 2005.
This article has been cited by other articles:
|
|
 |
|
  S. Margeridon, S. Carrouee-Durantel, I. Chemin, L. Barraud, F. Zoulim, C. Trepo, and A. Kay Rolling Circle Amplification, a Powerful Tool for Genetic and Functional Studies of Complete Hepatitis B Virus Genomes from Low-Level Infections and for Directly Probing Covalently Closed Circular DNA Antimicrob. Agents Chemother., September 1, 2008; 52(9): 3068 - 3073. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Lada, Y. Benhamou, T. Poynard, and V. Thibault Coexistence of Hepatitis B Surface Antigen (HBs Ag) and Anti-HBs Antibodies in Chronic Hepatitis B Virus Carriers: Influence of "a" Determinant Variants J. Virol., March 15, 2006; 80(6): 2968 - 2975. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |
GT, 
FP, 
